Painful small-fiber neuropathy in Sjogren syndrome
Chai J, Herrmann DN, Stanton M, Barbano RL, Logigian EL.
Department of Neurology, University of Rochester, Rochester, NY, USA.
Neurology. 2005 Sep 27;65(6):925-7
Of 20 consecutive patients with Sjogren neuropathy, 16 (80%) presented with burning feet and 12 (60%) with non-length-dependent sensory symptoms. Leg and thigh skin biopsies, performed in 13 patients, including 7 with normal electrophysiology, showed either reduced epidermal nerve fiber (ENF) density or abnormal morphology. ENF loss was frequently non length dependent, suggesting that patients with this disorder commonly have a small-fiber sensory neuronopathy rather than a "dying-back" axonopathy.
PMID: 16186536 [PubMed - indexed for MEDLINE]
A no of docs (about 5 or more) have suggested I had Sjogren's from my symptoms, and left it at that. I have never had specific tests for it though?
It was intermittent though, always there to a degree but waxing and waning in severity...i was told this is the normal course.
Since taking B1 for 3 months (by injection), I am pleased to say I no longer have Sjogren's symptoms!! They have gradually reduced and , maybe another 10% -20% moistness would be better, but its really OK!
I'm also on oestrogen though and I think I've worked out before this helps.. but I've never reached a remission this good for quite a while.
Fingers crossed!
I still have some feet burning and neuropathy (numbness/pain etc), , and a little in lips and hands but not really that noticeable..bottom of legs still scaly and dry.
Eyes now moist as I need, and stinging stopped almost..still red though, more so at some times than others.. never clear
Moist in mouth and skin still dry but much better..
Hoping this continues, and looking out for anything relating thiamin to Sjrogen's now too..--------------------------------------
Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients.Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, Dubucquoi S, Pruvo JP, Vermersch P, Hatron PY.
Department of Neurology, CHRU Lille, France.
Neurologic involvement occurs in approximately 20% of patients with primary Sjogren syndrome (SS). However, the diagnosis of SS with neurologic involvement is sometimes difficult, and central nervous system (CNS) manifestations have been described rarely. We conducted the current study to describe the clinical and laboratory features of SS patients with neurologic manifestations and to report their clinical outcome. We retrospectively studied 82 patients (65 women and 17 men) with neurologic manifestations associated with primary SS, as defined by the 2002 American-European criteria. The mean age at neurologic onset was 53 years. Neurologic involvement frequently preceded the diagnosis of SS (81% of patients). Fifty-six patients had CNS disorders, which were mostly focal or multifocal. Twenty-nine patients had spinal cord involvement (acute myelopathy [n = 12], chronic myelopathy [n = 16], or motor neuron disease [n = 1]). Thirty-three patients had brain involvement and 13 patients had optic neuropathy.
The disease mimicked relapsing-remitting multiple sclerosis (MS) in 10 patients and primary progressive MS in 13 patients.
We also recorded diffuse CNS symptoms: some of the patients presented seizures (n = 7), cognitive dysfunction (n = 9), and encephalopathy (n = 2). Fifty-one patients had peripheral nervous system involvement (PNS). Symmetric axonal sensorimotor polyneuropathy with a predominance of sensory symptoms or pure sensory neuropathy occurred most frequently (n = 28), followed by cranial nerve involvement affecting trigeminal, facial, or cochlear nerves (n = 16). Multiple mononeuropathy (n = 7), myositis (n = 2), and polyradiculoneuropathy (n = 1) were also observed. Thirty percent of patients (all with CNS involvement) had oligoclonal bands. Visual evoked potentials were abnormal in 61% of the patients tested. Fifty-eight patients had magnetic resonance imaging (MRI) of the brain. Of these, 70% presented white matter lesions and 40% met the radiologic criteria for MS. Thirty-nine patients had a spinal cord MRI. Abnormalities were observed only in patients with spinal cord involvement. Among the 29 patients with myelopathy, 75% had T2-weighted hyperintensities. Patients with PNS manifestations had frequent extraglandular complications of SS. Anti-Ro/SSA or anti-La/SSB antibodies were detected in 21% of patients at the diagnosis of SS and in 43% of patients during the follow-up (mean follow-up, 10 yr). Biologic abnormalities were more frequently observed in patients with PNS involvement than in those with CNS involvement. Fifty-two percent of patients had severe disability, and were more likely to have CNS involvement than PNS involvement. Treatment by cyclophosphamide allowed a partial recovery or stabilization in patients with myelopathy (92%) or multiple mononeuropathy (100%). The current study underlines the diversity of neurologic complications of SS. The frequency of neurologic manifestations revealing SS and of negative biologic features, especially in the event of CNS involvement, could explain why SS is frequently misdiagnosed. Screening for SS should be systematically performed in cases of acute or chronic myelopathy, axonal sensorimotor neuropathy, or cranial nerve involvement. The outcome is frequently severe, especially in patients with CNS involvement. Our study also underlines the efficacy of cyclophosphamide in myelopathy and multiple neuropathy occurring during SS. Copyright 2004 Lippincott Williams & Wilkins
PMID: 15342972 [PubMed - indexed for MEDLINE]
maybe that's what I had with the remitting-relapsing MS symptoms since about 30ish ?..when my health problems really started?
I still have this hypothesis that diabetic neuropathy may be helped by Low B1.. caused maybe by high glucose levels in blood that may be reducable by B1 supplementation?
Small fiber neuropathy and neurovascular disturbances in diabetes mellitus.Vinik AI, Erbas T, Stansberry KB, Pittenger GL.
Strelitz Diabetes Research Institutes, Department of Medicine and Pathology/Anatomy/Neurobiology, Eastern Virginia Medical School, Norfolk, Virginia, USA.
Functional and organic abnormalities in small unmyelinated C fibers are the hallmark of type 2 diabetes. These may be silent clinically or present with burning feet, neurovascular abnormalities, wherein warm, cold, and heat pain thresholds are disturbed in association with impairment in skin blood flow and loss of PGP 9.5 immunostaining nerves in the skin. There is a dysfunctional phase preceding organic structural damage to the neurovascular unit. It coexists with elements of the metabolic syndrome, particularly insulin resistance (IR), elevated systolic blood pressure, and diabetic dyslipidemia i.e. dysfunction of the neurovascular unit may contribute to IR due to compromised blood flow with decreased delivery of fuels to their target tissues. If this proves to be the case, it will become important to re-focus energies on the defective neuropeptidergic regulation of blood flow as an approach to ameliorating diabetes. Because there is a functional phase that precedes structural damage, reversibility of the defect is achievable.
PMID: 11460591 [PubMed - indexed for MEDLINE]
My PN-feet burning is gradually reducing but is still there all the time, intensity varies; and so far I havn't been able to pick why?.. it could be getting better slowly with this B1 therapy?.. hopefully. I guess if nerves have been damaged it may take a while to regrow etc.. well sure hope they do!
---------------------
Postgrad Med. 1989 Jun;85(8):301-6.
Thiamine deficiency neuropathy. It's still common today.Skelton WP 3rd, Skelton NK.
James A. Haley Veterans Hospital, Tampa, FL 33612.
Despite the fact that thiamine deficiency neuropathy is increasing in incidence in our society, it remains an underdiagnosed disorder. The typical complaints of weakness and burning feet are often regarded as trivial by the attending physician. Electrophysiologic studies are sensitive and often provide supportive evidence to aid in the diagnosis. Since chronic pain therapy is often ineffective, a high index of suspicion should be maintained to help ensure early diagnosis and successful intervention.
PMID: 2542916 [PubMed - indexed for MEDLINE]
--------------------------
2: PAGANONI C. Related Articles, Links
[Cocarboxylase in the treatment of the Gougerot-Howers-Sjogren syndrome.]
Ann Ottalmol Clin Ocul. 1961 Nov;87:663-6. Italian. No abstract available.
PMID: 14483145 [PubMed - OLDMEDLINE for Pre1966]
I haven't as yet tried to get this paper.. plus I don't read Italian
but it MAY say there is a link..known back in 1960's but since forgotten?
maybe they use B1 therapy for Sjrogen's??
note cocarboxylase is an enzyme that needs B1.
---------------------------------
If its just a remission its the best I've been in for a while :-), and it keeps improving!
Rheumatology 2001; 40: 1085-1088
Outcome measures in Sjögren's syndrome